


# Lung Health Study





Korea Med Synapse

Hardy Kornfeld, MD  
Division of Pulmonary, Allergy and Critical Care  
UMass Chan Medical School  
Worcester, MA, USA

# What Lungs Do

- Ventilation
- Perfusion
- Gas exchange



VC → RA → RV → PA → alveolar capillaries   pulmonary veins → LA → LV → aorta

# Long TB

Estimated 155M TB survivors alive in 2020 (Dodd, *Lancet Infect Dis* 2021)

- Pooled standardized mortality ratio for TB survivors 2.9 vs people without TB (Romonowski, *Lancet Infect Dis* 2019)
- Lifetime burden of disease after TB (Menzies, *Lancet Glob Health* 2021)
  - Estimated 98-151M DALYs due to incident TB
  - 12.1 DALYs per incident case, with 6.3 from disease episode and 5.8 from post-TB sequelae
  - Greatest burden in younger people from high TB incidence countries
- Cardiovascular disease
  - Taiwan NHIRD: aHR 1.40 for ACS overall, 6.58 for age 41-64, and 10.20 for age  $\geq 65$  (Chung, *IJTL* 2014)
- Lung cancer
  - aHR 1.72 in 4.8 yrs overall; aHR 6.78 in 20 pack-yr smokers (Moon, *Clin Infect Dis* 2023)
- Autoimmunity?

# Post-TB Lung Disease

Evidence of chronic respiratory abnormality, with or without symptoms, attributable at least in part to prior TB  
- 1<sup>st</sup> International Post-Tuberculosis Symposium, 2020

- PTLD prevalence reported in 18-87% of survivors across multiple studies (median > 50%)
- Obstructive, restrictive, and mixed ventilatory defects in various proportions
- Worse function with DR-TB
- Worse function with smoking history
- Worse function in rural vs urban settings in some studies
- Median values improve over time during and after treatment
- Prior TB significantly associated with COPD diagnosis (OR=3.05) (Byrne, Int J Infect Dis 2021)
  - Strongest association in high TB burden countries, never smokers, younger people

# Mechanisms & Manifestations

- Collateral damage from immune response
- Matrix digestion, epithelial injury, bronchiolitis, pleuritis
- Fibrotic resolution benefited hosts before antibiotics
- Multiple cell types & pathways involved


- Pathologies

- Pneumonitis
  - Cavitation
  - Bronchiolitis
- } Acute phase

- Parenchymal fibrosis
  - Bronchiectasis
  - Pleural & pericardial fibrosis
- } Resolution

- Late sequelae

- COPD
- Restrictive ventilatory defect
- Aspergilloma
- Exacerbations of bronchiectasis
- Pulmonary hypertension



Left lung, superior lobe, and upper part of lower lobe, the former containing a number of communicating caverns, brought about by tuberculous infiltration, caseation, and evacuation of the contents through the bronchi: *A*, aneurysmal dilatation of an artery spanning one margin of a large cavity; *B*, communication with another cavity; *C, C*, thickened and adherent pleura between the two involved lobes. The pleura over both lobes is thickened, and at the autopsy the cavity had been obliterated by universal adhesion; *D*, a small group of tubercles in which caseation is just beginning; *E*, a fused group of tubercles, farther advanced than at *D*. (Hara.)

# Gaps


- Plethora of studies with **small cohorts** at one or **few sites**
- Limited assessment of clinical & demographic **PTLD risk associations**
- Very limited assessment of **pediatric PTLD**
- Studies limited to short **timespan** post-TB
- Limited **mechanistic studies**
  - Roles for neutrophils, NETs, inflammatory macrophages, T cells, fibrocytes & MMT, metalloproteinases, TGFb, pro-resolving mediators
  - *Mtb* genotype associations?
- **Criteria for interventional trial participant selection**



## What to Measure

Parameter	Pros	Cons
Peak flow	Simple and inexpensive	Effort-dependent Limited information
Spirometry	Fundamental PFT data Standardized, \$\$	Effort-dependent Transmission risk
Lung volumes	Accurate diagnosis of restrictive defects, \$\$\$	Requires a body box Transmission risk
DLCO	Accurate diagnosis of diffusion defects, \$\$	Effort-dependent Transmission risk
Exercise (±oximetry)	Simple and inexpensive Cardiovascular function	Low sensitivity for mild impairment
QoL instruments	Simple and inexpensive	Administration time, nonspecific
CXR, CT, PET	Structural correlate \$, \$\$, \$\$\$, respectively	You get what you pay for Radiation, glucose

# Why measure lung health?






# RePORT India Aim 3

DJ Christopher & Akshay Gupte

1. Functional & morphological phenotypes of ATLD & PTLD.
2. Association between lung injury markers & treatment outcomes
3. Plasma & sputum inflammatory markers of lung injury & PTLD

Prospective cohort study at 5 sites  
Adults with DS-TB and no prior TB or chronic lung disease  
325 participants evaluated for 18 months (M0, 2, 6, 12, 18)

Aim 1: spirometry, 6MWT, QoL  
Subset: TLC, DLCO, CT, PET, cytokines



Aim 3: Inflammatory markers associated with lung injury & impairment during and after treatment

Aim 2: Association of clinical & imaging markers with outcomes


# Why they call it re-search

Lincoln NS, Bosworth EB, Alling DW. The after-history of pulmonary tuberculosis. III. Minimal tuberculosis. *Am Rev Tuberc* 1954; 70:15-31.


Alling DW, Lincoln NS, Bosworth EB. The after-history of pulmonary tuberculosis. V. Moderately advanced tuberculosis. *Am Rev Tuberc* 1954; 70:995-1008.

Alling DW, Bosworth EB, Lincoln NS. The after-history of pulmonary tuberculosis. IV. Far advanced tuberculosis. *Am Rev Tuberc* 1955; 71:519-528.

# How to measure (spirometry)




- Low FEV1/FVC ratio = obstructive ventilatory defect
- Low FEV1 & FVC suggests restrictive ventilatory defect
- % predicted values correct for age, sex, race, and height
- 10% change is clinically significant
- PRISm (FEV1/FVC  $\geq 0.70$  with FEV1 < 80% predicted)



## Subjective measures

- QoL instruments (St. George's, CAT)
- MRC dyspnea scale

# ACS risk/time



**Figure** Probability of being free of ACS development for patients with (dashed line) or without (solid line) tuberculosis. ACS = acute coronary syndrome.